Effect of body mass index on N-terminal pro-brain natriuretic peptide values in patients with heart failure
- PMID: 37642755
- PMCID: PMC10465415
- DOI: 10.1186/s43044-023-00401-1
Effect of body mass index on N-terminal pro-brain natriuretic peptide values in patients with heart failure
Abstract
Background: N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a biomarker used for the diagnosis of heart failure. There is a relationship between NT-proBNP levels and body mass index (BMI). The study aimed to explore the impact of BMI on NT-proBNP concentrations and to examine whether other factors independent of or combined with BMI affect NT-proBNP values in patients with heart failure.
Results: A total of 293 participants were recruited. The mean age was 68.9 ± 13.2 years, males accounted for 46.4% of the total cohort, the mean BMI was 23.1 ± 4.0 kg/m2, and the median NT-proBNP level was 3776 (1672-8806) pg/ml. There was an inverse relationship between BMI and log NT-proBNP (r = - 0.29; p < 0.001, Spearman correlation). Each standard deviation increase in BMI (4 kg/m2) was associated with a 7% decrease in NT-proBNP values in the total cohort. The independent inverse determinants of NT-proBNP other than BMI were male gender and eGFR, while the variables directly correlated to NT-proBNP were LVEF ≤ 40% and NYHA class III-IV heart failure.
Conclusions: There is an inverse association between BMI and NT-proBNP levels. However, the correlation is weak, and there are other variables that have a significant impact on the NT-proBNP values as well. The NT-proBNP levels are still valuable in the diagnosis of heart failure regardless of BMI status.
Keywords: Body mass index (BMI); Heart failure; N-terminal pro-B-type natriuretic peptide (NT-proBNP); Obesity.
© 2023. Egyptian Society of Cardiology.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
Similar articles
-
Interaction of Body Mass Index on the Association Between N-Terminal-Pro-b-Type Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure).J Am Heart Assoc. 2018 Feb 3;7(3):e006740. doi: 10.1161/JAHA.117.006740. J Am Heart Assoc. 2018. PMID: 29431103 Free PMC article.
-
Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.J Am Coll Cardiol. 2007 Nov 13;50(20):1973-80. doi: 10.1016/j.jacc.2007.08.012. Epub 2007 Oct 29. J Am Coll Cardiol. 2007. PMID: 17996563
-
N-terminal pro-B-type natriuretic Peptide in overweight and obese patients with and without diabetes: an analysis based on body mass index and left ventricular geometry.Korean Circ J. 2009 Dec;39(12):538-44. doi: 10.4070/kcj.2009.39.12.538. Epub 2009 Dec 30. Korean Circ J. 2009. PMID: 20049140 Free PMC article.
-
N-Terminal Pro-Brain Natriuretic Peptide and Heart Failure Risk Among Individuals With and Without Obesity: The Atherosclerosis Risk in Communities (ARIC) Study.Circulation. 2016 Feb 16;133(7):631-8. doi: 10.1161/CIRCULATIONAHA.115.017298. Epub 2016 Jan 8. Circulation. 2016. PMID: 26746175 Free PMC article.
-
Use of B-Type Natriuretic Peptide (BNP) and N-Terminal proBNP (NT-proBNP) as Diagnostic Tests in Adults With Suspected Heart Failure: A Health Technology Assessment.Ont Health Technol Assess Ser. 2021 May 6;21(2):1-125. eCollection 2021. Ont Health Technol Assess Ser. 2021. PMID: 34055110 Free PMC article.
Cited by
-
Cardiac Biomarkers Predict Major Adverse Cardiac Events (MACE) in Incident Haemodialysis Patients: Results from a Global Federated Database.Biomedicines. 2025 Feb 5;13(2):367. doi: 10.3390/biomedicines13020367. Biomedicines. 2025. PMID: 40002781 Free PMC article.
References
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous